| Literature DB >> 30950215 |
Stefan Riedel1,2,3, Nicholas Boire3, Kathryn A Carson4, Aravinda Vadlamudi3, Joshua Khuvis3, Vivek Vadlamudi3, Vajini Atukorale3, Victoria A A Riedel3, Nicole M Parrish3.
Abstract
In recent years, the rise in antimicrobial resistance (AR) in the healthcare setting as well as the environment has been recognized as a growing public health problem. The Chesapeake Bay (CB) and its upper tributaries (UT) is a large and biologically diverse estuary. This pilot study evaluated the presence of AR of gram-negative bacteria isolated from water samples collected at various sites of the Chesapeake Bay. Bacterial organisms were identified and antimicrobial susceptibility testing was performed by phenotypic and genotypic methods. Ninety-two distinctly different gram-negative bacteria were identified; Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, and Escherichia coli were most often isolated. Serratia marcescens was more frequently isolated in samples from the UT compared to the CB. Antimicrobial resistance was more frequently detected in organisms from the CB by phenotypic and genotypic methods. Antimicrobial resistance to ampicillin, imipenem, tetracycline, and chloramphenicol were the most frequently observed resistance patterns. ACT-1, CMY, and SHV genes were the most frequently detected resistance genes, with predominance in organism isolated from the CB. The results from this study emphasize the importance for further developing comprehensive surveillance programs of AR in bacterial isolates in the various environments, such as recreational and other water systems.Entities:
Keywords: Chesapeake Bay; Enterobacteriaceae; One Health; antibiotic pollution; antimicrobial resistance
Mesh:
Substances:
Year: 2019 PMID: 30950215 PMCID: PMC6741119 DOI: 10.1002/mbo3.839
Source DB: PubMed Journal: Microbiologyopen ISSN: 2045-8827 Impact factor: 3.139
Figure 1Water sampling sites and global positioning system 1 (GPS) coordinates for surface water samples collected from the Chesapeake Bay and adjacent Upper Tributaries
Gram‐negative bacterial isolates recovered from the various sampling sites on the Chesapeake Bay and the adjacent watershed
|
Bacterial Organism [ | Chesapeake Bay sampling sites ( | Upper Tributary sampling sites ( | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North Point State Park | Baltimore Inner Harbor | Eastern Neck Wildlife Preserve | Sandy Point State Park | Gunpowder State Park | Monocacy River | Catoctin Creek | Potomac River | Shenandoah River | Point of Rocks | ||||||
| Proximal | Distal | Proximal | Distal | Proximal | Distal | Proximal | Distal | Proximal | Distal | ||||||
|
| 0 | 0 | 3 | 3 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 0 | 0 |
|
| 3 | 0 | 3 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 0 | 3 | 0 | 0 |
|
| 0 | 1 | 0 | 0 | 2 | 0 | 1 | 4 | 0 | 0 | 1 | 1 | 0 | 5 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 5 | 1 | 5 |
|
| 0 | 2 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 3 | 2 | 0 |
|
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
|
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Total number of isolates (%) | 7 (7.6%) | 4 (4.4%) | 6 (6.5%) | 5 (5.4%) | 5 (5.4%) | 2 (2.2%) | 4 (4.4%) | 8 (8.7%) | 5 (5.4%) | 5 (5.4%) | 4 (4.4%) | 8 (8.7%) | 14 (15.2%) | 8 (8.7%) | 7 (7.6%) |
Antimicrobial resistance by phenotypic AST methods detected in gram‐negative bacterial organisms, listed by antimicrobial agent and geographic site of isolation
| Antimicrobial agent [MIC (µg/mL) interpretation] | Modal MIC (µg/mL) [Range] | |
|---|---|---|
| Chesapeake bay sampling sites | Upper tributary sampling sites | |
|
Ampicillin | 16 [4–≥256] | 32 [8–≥256] |
|
Piperacillin/Tazobactam | 4 [0.5–64] | 2 [1–8] |
|
Ceftriaxone | 0.25 [0.047–1] | 0.125 [0.047–0.25] |
|
Ceftaroline | 0.25 [0.006–0.5] | 0.5 [0.064–0.25] |
|
Cefepime | 0.064 [0.047–1] | 0.064 [0.047–1] |
|
Ertapenem | 0.032 [0.012–1] | 0.032 [0.004–1] |
|
Imipenem | 0.5 [0.125–16] | 0.5 [0.125–8] |
|
Meropenem | 0.064 [0.012–8] | 0.064 [0.012–0.064] |
|
Doripenem | 0.064 [0.023–1] | 0.064 [0.012–4] |
|
Gentamicin | 1 [0.25–8] | 0.5 [0.125–4] |
|
Amikacin | 4 [2–16] | 4 [1–4] |
|
Ciprofloxacin | 0.032 [0.016–0.25] | 0.032 [0.016–0.25] |
|
Tetracycline | 4 [1 ‐ ≥256] | 4 [1 ‐ ≥256] |
|
Trimethoprim/Sulfamethoxazole | 0.125 [0.064–2] | 0.25 [0.064–0.5] |
|
Chloramphenicol | 8 [0.5–256] | 8 [2–128] |
MIC interpretive criteria, based on CLSI M100‐S25; Clinical and Laboratory Standards Institute (CLSI). (2016); S: susceptible; SDD: susceptible, dose‐dependent; I: intermediate susceptible; R: resistant.
Phenotypic antimicrobial resistance (I + R) of bacteria, overall and by locationa
| Antimicrobial Agent tested against GNR isolated ( |
Antimicrobial Resistance (I + R) by Location | |||
|---|---|---|---|---|
|
All Locations |
Chesapeake Bay |
Upper Tributary |
| |
| Ampicillin ( | 70 (78) | 38 (78) | 32 (78) | 0.99 |
| Ceftaroline | 8 (9) | 3 (6) | 5 (12) | 0.46 |
| Ceftriaxone | 4(4) | 2 (4) | 2 (5) | 0.99 |
| Cefepime | 3 (3) | 3 (6) | 0 (0) | 0.25 |
| Imipenem | 15 (17) | 12 (24) | 3 (7) | 0.045 |
| Doripenem | 1 (1) | 0 (0) | 1 (2) | 0.46 |
| Ertapenem ( | 4 (4) | 3 (6) | 1 (2) | 0.62 |
| Meropenem | 2 (2) | 2 (4) | 0 (0) | 0.16 |
| Pip/Tazo ( | 3 (3) | 3 (6) | 0 (0) | 0.50 |
| Chloramphenicol | 28 (31) | 14 (29) | 14 (34) | 0.65 |
| Amikacin | 0 (0) | 0 (0) | 0 (0) | — |
| Gentamicin | 1 (1) | 1 (2) | 0 (0) | 0.99 |
| Ciprofloxacin | 1 (1) | 1 (2) | 0 (0) | 0.99 |
| Tetracycline | 37 (41) | 17 (35) | 20 (49) | 0.20 |
p value is from Fisher's exact test; p < 0.05 is considered significant.
Pip/Tazo: Piperacillin/Tazobactam.
GNR: Gram‐negative rod (bacteria); one Aeromonas isolate and one Plesiomonas isolate were not tested against ampicillin, ertapenem as per CLSI guidelines.
Antimicrobial resistance (I + R) based on MIC interpretive criteria of CLSI M‐100 S25 (2016).
Resistance genes detected by the Acuitas test in gram‐negative bacterial organisms, listed by bacterial organisms and geographic site of isolation
| Bacterial Organism (# isolated) | Chesapeake Bay sampling sites | Upper Tributary sampling sites | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| North Point State Park | Baltimore Inner Harbor | Eastern Neck Wildlife Preserve | Sandy Point State Park | Gunpowder State Park | Monocacy River | Catoctin Creek | Potomac River | Shenandoah River | Point of Rocks | |
|
| “x” |
SHV‐G156 | SHV‐G156 |
SHV‐G156 | SHV‐G156 |
SHV‐G156 | “x” | “x” | “x” | “x” |
|
|
ACT‐1/MIR‐1 CMY‐2/CFE‐1 | ACT‐1/MIR‐1 | “x” | ACT‐1/MIR‐1 |
ACT‐1/MIR‐1 | “x” | “x” | “x” | “x” | “x” |
|
| “x” | “x” | “x” | SHV‐G156 | “x” | “x” | “x” | “x” | “x” | “x” |
|
| “x” | “x” | “x” | “x” | ACT‐1/MIR‐1 | “x” | “x” | “x” | “x” | “x” |
|
|
CMY‐2/CFE‐1 |
CMY‐2/CFE‐1 |
CMY‐2/CFE‐1 | “x” | “x” | “x” |
CMY‐2/CFE‐1 |
CMY‐2/CFE‐1 | CMY‐2/CFE‐1 | “x” |
|
|
CMY‐2/CFE‐1 | “x” | “x” | “x” | “x” |
CMY‐2/CFE‐1 | “x” | “x” | “x” |
CMY‐2/CFE‐1 |
|
| “x” | “x” |
CMY‐2/CFE‐1 | “x” | “x” | “x” | “x” | “x” | “x” | “x” |
|
| “x” |
CMY‐2/CFE‐1 | “x” | “x” | “x” | “x” | “x” | DHA‐1 | “x” | “x” |
|
| “x” | “x” | SHV‐G156 | “x” | “x” | “x” | “x” | “x” | “x” | “x” |
|
| “x” | “x” | “x” | MOX‐1 | “x” | “x” | “x” | “x” | “x” | “x” |
ACT‐1/MIR‐1, CMY‐2/CFE‐1, CMY‐70/CFE‐1, DHA‐1, MOX‐1: plasmid‐mediated Amp‐C beta‐lactamases; CMY‐47: chromosomal‐encoded Amp‐C beta‐lactamase; SHV‐G156 and SHV‐G238: chromosomally‐ and plasmid‐encoded β‐lactamases; “x”: no resistance gene detected by Acuitas AMR panel.
Genotypic detection of antimicrobial resistance of bacteria, overall and by location
| Resistance Gene |
All Locations |
Chesapeake |
Upper Tributary |
|
|---|---|---|---|---|
| Any | 46 (51) | 35 (71) | 11 (27) | <0.001 |
| ACT‐1 | 8 (9) | 8 (16) | 0 (0) | 0.007 |
| CMY‐2 | 22 (24) | 12 (24) | 10 (24) | 0.99 |
| CMY‐47 | 9 (10) | 6 (12) | 3 (7) | 0.50 |
| CMY‐70 | 16 (18) | 8 (16) | 8 (20) | 0.78 |
| DHA‐1 | 1 (1) | 0 (0) | 1 (2) | 0.46 |
| MOX‐1 | 0 (0) | 0 (0) | 0 (0) | — |
| OXA‐50 | 0 (0) | 0 (0) | 0 (0) | — |
| SHV‐G156 | 15 (17) | 14 (29) | 1 (2) | 0.001 |
| SHV‐G238 | 8 (9) | 7 (14) | 1 (2) | 0.07 |
p value is from Fisher's exact test; p < 0.05 is considered significant.
Resistance genes: ACT‐1/MIR‐1, CMY‐2/CFE‐1, CMY‐70/CFE‐1, DHA‐1, MOX‐1: plasmid‐mediated Amp‐C β‐lactamases; CMY‐47: chromosomal‐encoded Amp‐C β‐lactamase; SHV‐G156 and SHV‐G238: chromosomally‐ and plasmid‐encoded β‐lactamases.